---
layout: post
title: "Purple Book Enhancement; Establishment of a Public Docket; Request for Comments"
date: 2026-02-05 19:08:49 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2020-04539
original_published: 2020-03-05 00:00:00 +0000
significance: 8.00
---

# Purple Book Enhancement; Establishment of a Public Docket; Request for Comments

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 05, 2020 00:00 UTC
**Document Number:** 2020-04539

## Summary

The Food and Drug Administration (FDA or Agency) announced the completion of the first phase of the enhanced Purple Book on February 24, 2020. FDA is transitioning the current table format "Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations" to a searchable, public-facing online database entitled "Purple Book: Database of FDA-Licensed Biological Products." FDA is establishing a docket for public comment to gather stakeholder feedback on the new database to inform the next phase of development.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/03/05/2020-04539/purple-book-enhancement-establishment-of-a-public-docket-request-for-comments)
- API: https://www.federalregister.gov/api/v1/documents/2020-04539

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
